S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.73 (-0.77%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.95 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-2.06%)
GE   106.30 (+0.22%)
DIS   91.93 (-0.65%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.73 (-0.77%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.95 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-2.06%)
GE   106.30 (+0.22%)
DIS   91.93 (-0.65%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.73 (-0.77%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.95 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-2.06%)
GE   106.30 (+0.22%)
DIS   91.93 (-0.65%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.73 (-0.77%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.95 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-2.06%)
GE   106.30 (+0.22%)
DIS   91.93 (-0.65%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)

Prothena (PRTA) Price Target & Analyst Ratings

$69.50
-0.45 (-0.64%)
(As of 05:16 PM ET)
Compare
Today's Range
$68.72
$70.60
50-Day Range
$48.26
$78.59
52-Week Range
$21.06
$79.65
Volume
281,158 shs
Average Volume
478,777 shs
Market Capitalization
$3.67 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$86.33

Prothena Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 9 Analyst Ratings

Consensus Analyst Price Target

$86.33
24.22% Upside
High Prediction$120.00
Average Prediction$86.33
Low Prediction$55.00
TypeCurrent
6/9/22 to 6/9/23
1 Month Ago
5/10/22 to 5/10/23
3 Months Ago
3/11/22 to 3/11/23
1 Year Ago
6/9/21 to 6/9/22
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
9 Buy rating(s)
7 Buy rating(s)
8 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$86.33$86.33$82.50$67.89
Predicted Upside24.22% Upside54.18% Upside52.76% Upside17.38% Upside
Get Prothena Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter.


PRTA Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

PRTA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Prothena Stock vs. The Competition

TypeProthenaMedical CompaniesS&P 500
Consensus Rating Score
2.89
2.66
2.48
Consensus RatingModerate BuyBuyHold
Predicted Upside24.78% Upside1,163.64% Upside250.58% Upside
News Sentiment RatingNeutral News
Neutral News
Positive News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/8/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$98.00 ➝ $120.00+52.69%
5/5/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$75.00 ➝ $90.00+28.28%
4/24/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Li
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
4/24/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$80.00+46.74%
2/27/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$76.00 ➝ $72.00+31.94%
1/27/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$94.00+68.31%
11/15/2022Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$110.00 ➝ $120.00+97.30%
11/4/2022Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Sector Perform$52.00 ➝ $55.00-4.66%
9/28/2022Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Tazeen Ahmad
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$45.00 ➝ $65.00+13.98%
9/28/2022JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$50.00 ➝ $81.00+66.77%
(Data available from 6/9/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












PRTA Price Target - Frequently Asked Questions

What is Prothena's consensus rating and price target?

According to the issued ratings of 9 analysts in the last year, the consensus rating for Prothena stock is Moderate Buy based on the current 1 hold rating and 8 buy ratings for PRTA. The average twelve-month price prediction for Prothena is $86.33 with a high price target of $120.00 and a low price target of $55.00. Learn more on PRTA's analyst rating history.

Do Wall Street analysts like Prothena more than its competitors?

Analysts like Prothena more than other Medical companies. The consensus rating for Prothena is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how PRTA compares to other companies.

Does Prothena's stock price have much upside?

According to analysts, Prothena's stock has a predicted upside of 49.46% based on their 12-month price targets.

What analysts cover Prothena?

Prothena has been rated by Cantor Fitzgerald, HC Wainwright, SVB Leerink, and SVB Securities in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:PRTA) was last updated on 6/9/2023 by MarketBeat.com Staff

My Account -